Searcharxiv⌕ Search

arXiv subjects

Sivaraman Rajaganapathy

Publications and source records attributed to Sivaraman Rajaganapathy.

3 recordsLinked to original sources

Enhancing Lung Cancer Treatment Outcome Prediction through Semantic Feature Engineering Using Large Language Models

Accurate prediction of treatment outcomes in lung cancer remains challenging due to the sparsity, heterogeneity, and contextual overload of real-world electronic health data. Traditional models often fail to capture semantic information across multimodal streams, while large-scale fine-tuning approaches are impractical in clinical workflows. We introduce a framework that uses Large Language Models (LLMs) as Goal-oriented Knowledge Curators (GKC) to convert laboratory, genomic, and medication data into high-fidelity, task-aligned features. Unlike generic embeddings, GKC produces representations tailored to the prediction objective and operates as an offline preprocessing step that integrates naturally into hospital informatics pipelines. Using a lung cancer cohort (N=184), we benchmarked GKC against expert-engineered features, direct text embeddings, and an end-to-end transformer. Our approach achieved a mean AUROC of 0.803 (95% CI: 0.799-0.807) and outperformed all baselines. An ablation study further confirmed the complementary value of combining all three modalities. These results show that the quality of semantic representation is a key determinant of predictive accuracy in sparse clinical data settings. By reframing LLMs as knowledge curation engines rather than black-box predictors, this work demonstrates a scalable, interpretable, and workflow-compatible pathway for advancing AI-driven decision support in oncology.

cs.LG↗

Launching Insights: A Pilot Study on Leveraging Real-World Observational Data from the Mayo Clinic Platform to Advance Clinical Research

Backgrounds: Artificial intelligence (AI) is transforming healthcare, yet translating AI models from theoretical frameworks to real-world clinical applications remains challenging. The Mayo Clinic Platform (MCP) was established to address these challenges by providing a scalable ecosystem that integrates real-world multiple modalities data from multiple institutions, advanced analytical tools, and secure computing environments to support clinical research and AI development. Methods: In this study, we conducted four research projects leveraging MCP's data infrastructure and analytical capabilities to demonstrate its potential in facilitating real-world evidence generation and AI-driven clinical insights. Utilizing MCP's tools and environment, we facilitated efficient cohort identification, data extraction, and subsequent statistical or AI-powered analyses. Results: The results underscore MCP's role in accelerating translational research by offering de-identified, standardized real-world data and facilitating AI model validation across diverse healthcare settings. Compared to Mayo's internal Electronic Health Record (EHR) data, MCP provides broader accessibility, enhanced data standardization, and multi-institutional integration, making it a valuable resource for both internal and external researchers. Conclusion: Looking ahead, MCP is well-positioned to transform clinical research through its scalable ecosystem, effectively bridging the divide between AI innovation and clinical deployment. Future investigations will build upon this foundation, further exploring MCP's capacity to advance precision medicine and enhance patient outcomes.

cs.CY↗

Evaluation of GPT-3 for Anti-Cancer Drug Sensitivity Prediction

In this study, we investigated the potential of GPT-3 for the anti-cancer drug sensitivity prediction task using structured pharmacogenomics data across five tissue types and evaluated its performance with zero-shot prompting and fine-tuning paradigms. The drug's smile representation and cell line's genomic mutation features were predictive of the drug response. The results from this study have the potential to pave the way for designing more efficient treatment protocols in precision oncology.

cs.LG↗